Reports 14 Feb 2023
New frontiers in vaccinology
Learn about the latest advances in vaccine technology.
- Latest Posts
News and Trends 14 Feb 2023
Disc Medicine raises $62.5M for hematology programs
Disc Medicine, Inc., a U.S. clinical-stage biopharma company focused on the discovery, development and commercialization of treatments for patients suffering from serious hematologic diseases, has entered into a securities purchase agreement with investors resulting in an aggregate $62.5 million in gross proceeds through a registered direct offering. The financing was led by Bain Capital Life […]
News and Trends 14 Feb 2023
Scancell looking to partner after positive COVID vaccine data
Scancell Holdings plc, which develops novel immunotherapies for the treatment of cancer and infectious disease, has announced preliminary immunogenicity data from its phase 1 COVIDITY clinical trial at the University of Cape Town (UCT) Lung Institute in South Africa. The objectives of the trial were to assess the safety and immunogenicity of two vaccine candidates, […]
News and Trends 14 Feb 2023
Syena created to deliver first-in-class TCR-NK cell therapy
Replay, a genome writing company reprogramming biology by writing and delivering big DNA, and The University of Texas MD Anderson Cancer Center, have launched Syena, a new oncology-focused product company pioneering T-cell receptor (TCR) natural killer (NK) cell therapies (TCR-NKs). Building on the intellectual property and technology from MD Anderson and Replay, Syena has the […]
News and Trends 14 Feb 2023
IMV presents positive lymphoma trial results
IMV Inc. has announced positive preliminary data from its VITALIZE phase 2B trial. The study is evaluating IMV Inc. lead DPX product, maveropepimut-S (MVP-S), in combination with pembrolizumab, in patients with relapsed, refractory diffuse large B cell lymphoma (r/r DLBCL). IMV Inc. is a biopharmaceutical company developing a portfolio of immune-educating therapies based on its […]
News and Trends 14 Feb 2023
Minoryx Therapeutics announces X-linked adrenoleukodystrophy data
Minoryx Therapeutics has announced that data from its phase 2/3 ADVANCE clinical trial of lead candidate, leriglitazone, has been published in The Lancet Neurology. The trial, assessing the efficacy and safety of leriglitazone in male patients with adrenomyeloneuropathy, is the first and largest international study to enroll adult male X-linked adrenoleukodystrophy patients. X-linked adrenoleukodystrophy (X-ALD) […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 14 Feb 2023
Astex and Cardiff University Medicines Discovery Institute to collaborate on neurodegenerative diseases
Astex Pharmaceuticals (UK), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system and The Medicines Discovery Institute, Cardiff University (MDI) have entered into a multi-year, multi-million-pound drug discovery research collaboration, aimed to identify new drugs to treat neurodegenerative diseases. The collaboration […]
News and Trends 14 Feb 2023
BiPER Therapeutics raises €1.25M to develop small molecules to treat gastrointestinal cancers
BiPER Therapeutics, a French preclinical biotechnology company developing first-in-class drug candidates targeting BiP protein to treat gastrointestinal cancers, has raised €1.25 million ($1.35 million) in seed funding. BiPER Therapeutics received €300,000 in dilutive funds from WiSeed via WiClub Santé 2, €500,000 in convertible bonds from Bpifrance, and €450,000 in grants as part of the i-Lab […]
How efficient lab inventory management can become a driver for success
Lab inventory management is often not the first priority of biotech companies trying to stay ahead in a competitive environment. But according to a report released by the EU commission, the hidden costs of inefficient lab practices are estimated to exceed €10B every year. Novel lab inventory management solutions can thus reduce costs and push […]
News and Trends 10 Feb 2023
FDA approves GSK drug for recurrent or advanced mismatch repair-deficient endometrial cancer
GSK plc says the US Food and Drug Administration (FDA) has given full approval for Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by a US FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not […]
News and Trends 10 Feb 2023
Janssen reports positive topline phase 2 HDFN results
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced positive topline results from the proof-of-concept phase 2 open-label UNITY clinical trial for the treatment of pregnant adults at high risk for severe hemolytic disease of the fetus and newborn (HDFN). HDFN is a serious and rare condition that can cause life-threatening anemia in the […]
News and Trends 10 Feb 2023
Rocket Pharmaceuticals receives FDA RMAT designation for Danon disease gene therapy treatment
Rocket Pharmaceuticals, Inc says the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to RP-A501. RP-A501 is Rocket Pharmaceuticals’ investigational adeno-associated virus (AAV)-based gene therapy for the treatment of Danon disease, a devastating and fatal genetic cardiac disease for which there are no disease-altering therapies available. RMAT designation was […]
ADVERTISEMENT
